Dr. Shang-Chiung Chen obtained his Ph.D.
degree in the department of Molecular Pharmacology and Cancer
Therapeutics, Roswell Park Cancer Institute Graduate Division, SUNY
at Buffalo. During his time as a post-doctoral fellow in the Center
for Protein Therapeutics, he investigated the determinants
of the target-mediated disposition of anti-CEA antibodies.
Balthasar Laboratory,
School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, The
State University of New York